ATE491465T1 - Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen - Google Patents

Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen

Info

Publication number
ATE491465T1
ATE491465T1 AT05076809T AT05076809T ATE491465T1 AT E491465 T1 ATE491465 T1 AT E491465T1 AT 05076809 T AT05076809 T AT 05076809T AT 05076809 T AT05076809 T AT 05076809T AT E491465 T1 ATE491465 T1 AT E491465T1
Authority
AT
Austria
Prior art keywords
antigen
cells
activated
pbls
loaded
Prior art date
Application number
AT05076809T
Other languages
English (en)
Inventor
Babita Agrawal
Mark J Krantz
Mark A Reddish
Michael B Longenecker
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Application granted granted Critical
Publication of ATE491465T1 publication Critical patent/ATE491465T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05076809T 1997-05-08 1998-05-07 Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen ATE491465T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4594997P 1997-05-08 1997-05-08

Publications (1)

Publication Number Publication Date
ATE491465T1 true ATE491465T1 (de) 2011-01-15

Family

ID=21940709

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05076809T ATE491465T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
AT98921011T ATE394474T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98921011T ATE394474T1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen

Country Status (10)

Country Link
US (1) US6600012B1 (de)
EP (3) EP2341072A3 (de)
JP (1) JP4480800B2 (de)
AT (2) ATE491465T1 (de)
AU (1) AU727863B2 (de)
CA (1) CA2289742C (de)
DE (2) DE69839443D1 (de)
DK (1) DK1634949T3 (de)
ES (1) ES2357960T3 (de)
WO (1) WO1998050527A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906744A1 (de) * 1999-02-18 2000-08-24 Martin Roecken Verfahren zur Herstellung antitumoraler Th1-Zellen
WO2000061766A2 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
PT1210430E (pt) * 1999-09-08 2006-12-29 Imp Cancer Res Tech Péptidos derivados de muc-1
GB9921337D0 (en) 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
CA2441809C (en) * 2001-03-27 2014-07-22 Biomira, Inc. Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
AU2003225791A1 (en) 2002-03-15 2003-09-29 Department Of Veterans Affairs, Rehabilitation R And D Service Methods and compositions for directing cells to target organs
CA2482477A1 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
US20060142546A1 (en) * 2002-09-05 2006-06-29 Franz-Georg Hanisch Immunogenic muc1 glycopeptides
JP2006505554A (ja) * 2002-10-10 2006-02-16 デパートメント・オヴ・ヴェテランズ・アフェアズ 腫瘍特異的エピトープに向けられた、標識活性化リンパ球を使用した、腫瘍の検出、定位および染色
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
DK1697399T3 (en) 2003-12-12 2017-03-06 Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
US20080267963A1 (en) * 2004-11-02 2008-10-30 Biomedical Research Model, Inc. Methods of Cancer Treatment/Prevention Using Cancer Cell-Specific Surface Antigens
AU2006274651B2 (en) 2005-06-28 2012-09-27 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
RU2377994C1 (ru) * 2008-05-21 2010-01-10 Леонид Валентинович Загребин Способ иммунореабилитации онкозаболеваний
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
WO2011140595A2 (en) 2010-05-10 2011-11-17 4G Vaccines Pty Ltd Immunostimulatory and vaccine compositions
CA2825972A1 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
JP6523685B2 (ja) 2012-01-03 2019-06-05 アメリカ合衆国 Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ
KR20160007640A (ko) 2013-05-14 2016-01-20 메르크 파텐트 게엠베하 Muc-1 리포펩티드를 이용한 백신접종에 의한 폐암의 치료 방법
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (de) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
EP3986448A4 (de) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2614895A (en) 1994-06-13 1996-01-05 Unilever N.V. Bleach activation
AU710783B2 (en) * 1994-06-14 1999-09-30 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo T cell activation by antigen-pulsed dendritic cells
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
WO1996040066A1 (en) * 1995-06-07 1996-12-19 The Governors Of The University Of Alberta A METHOD FOR ELICITING A Th1-SPECIFIC IMMUNE RESPONSE
EP1012276A2 (de) 1997-02-24 2000-06-28 Therion Biologics Corporation Rekombinantes poxvirus zur immunisierung gegen muc1 tumor-assoziiertes antigen

Also Published As

Publication number Publication date
EP0986636A1 (de) 2000-03-22
EP1634949B1 (de) 2010-12-15
JP2001525668A (ja) 2001-12-11
EP0986636B1 (de) 2008-05-07
EP2341072A2 (de) 2011-07-06
US6600012B1 (en) 2003-07-29
ATE394474T1 (de) 2008-05-15
ES2357960T3 (es) 2011-05-04
CA2289742A1 (en) 1998-11-12
DE69842060D1 (de) 2011-01-27
AU7371298A (en) 1998-11-27
WO1998050527A1 (en) 1998-11-12
DK1634949T3 (da) 2011-03-28
AU727863B2 (en) 2001-01-04
EP1634949A1 (de) 2006-03-15
CA2289742C (en) 2013-07-16
EP2341072A3 (de) 2013-10-30
JP4480800B2 (ja) 2010-06-16
DE69839443D1 (de) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE491465T1 (de) Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
ATE325802T1 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
ATE330002T1 (de) Verfahren zur herstellung von membranvesikeln
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
IL219223B (en) Non-naturally occurring antigen-presenting cells (nnapc) derived from drosophila melanogaster cells for use in preparing a suspension of cd8+ cells and methods for their manufacture
PT2092938E (pt) Péptidos derivados de survivina e a sua utilização
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
CY1106400T1 (el) Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
EP1249490A3 (de) In vitro Aktivierung von cytotoxischen T Zellen
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
EP1470821A3 (de) Zelltherapieverfahren zur Behandlung von Tumoren
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
IL144265A0 (en) Use of antibodies for the vaccination against cancer
Slovin et al. Immunological approaches for the treatment of prostate cancer
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
WO2003039594A3 (en) Antigen presenting vesicles
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
PT1084246E (pt) Material biologico para a preparacao de composicoes destinadas ao tratamento de mamiferos
RU2000122041A (ru) Способ лечения злокачественных опухолей головного мозга
WO2000015767A3 (en) Antigen-presenting cells and their use in therapy
AR020765A1 (es) Anticuerpos monoclonales humanos contra el antigeno de tumor uk114 y celulas de linfocitos e hibridomas para su produccion
MX9606317A (es) Metodos para la activacion de celulas t in vivo por celulas dentriticas impulsadas por antigenos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1634949

Country of ref document: EP